Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure

Alloy Therapeutics Biogen collaboration

BOSTON — April 15, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, today announced a $40 million Series E financing round, marking a significant step in the company’s evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This […]

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Alloy Therapeutics Biogen collaboration

Boston, MA, April 7, 2026 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense […]

Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response

Cryo-Electron Microscopy

BOSTON — April 1, 2026 — Alloy Therapeutics today announced that Alexander Titus, Ph.D., has joined the company to lead its newly formed Vigilance Division, a strategic initiative focused on leveraging modern AI capabilities to enhance supply chain resilience, advance biosecurity preparedness, and accelerate the development of therapeutics for emerging biological threats.  The Vigilance Division […]

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

Alloy Therapeutics antibody discovery platform

BOSTON — March 17, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of […]

Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

Cryo-Electron Microscopy

BOSTON — January 6, 2026 — Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines.  Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level. Alloy’s AntiClastic technology is a proprietary cyclic nucleic acid […]

Alloy Therapeutics Announces Acquisition of Spannerwerks, a Leading Provider of Drug Development Consulting Services

Cryo-Electron Microscopy

BOSTON — October 23, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceuticals on the development and launch of new products. Under the terms of the agreement, Spannerwerks will operate […]

Alloy Therapeutics and University of British Columbia Partner to Accelerate Antibody Discovery with Cryo-Electron Microscopy Technology

Cryo-Electron Microscopy

Boston, MA and Vancouver, BC, October 2, 2025 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, and the University of British Columbia (UBC) announced a collaboration under which the two organizations will partner to accelerate the discovery of novel antibody therapeutics for pandemic preparedness applications. […]